RLT
RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
Emily MenendezRLT | October 9, 2024
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
Read More
Brian Rini, MD, FASCORLT | October 3, 2024
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
Christopher Wallis, MD, PhD, FRCSCCRPC | October 1, 2024
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
Karine Tawagi, MDCRPC | October 3, 2024
SPLASH continues to show benefit for PSMA RLT in mCRPC and adds to this consideration in the pre-chemotherapy setting.
Katy MarshallCRPC | October 3, 2024
177Lu-PSMA-617 is a PSMA-targeted radioligand therapy in patients with mCRPC.
Emily MenendezRLT | August 8, 2024
Multiple cycles of AcPSMA can cause side effects including salivary gland toxicity and xerostomia.
Vishnu MurthyCRPC | July 8, 2024
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Oliver Sartor, MDRLT | June 18, 2024
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Geoffrey Johnson, MD, PhDRLT | June 17, 2024
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Emily MenendezProstate Cancer | June 13, 2024
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Emily MenendezCRPC | June 13, 2024
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
Zachary BessetteRLT | June 11, 2024
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Brandon TwyfordRLT | June 10, 2024
Study shows [177Lu]Lu-PSMA is safe and effective for elderly patients with mCRPC, improving PSA response and overall survival
GU Oncology Now EditorsAdvancements in Oncology | June 13, 2024
Dr. Karine Tawagi focused this part of her discussion on 177Lu-PSMA-617 and the PSMAfore trial updates.
Michael Morris, MDRLT | June 4, 2024
Dr. Morris discusses a phase 1 study of JNJ-6420 for patients with mCRPC who received at least prior ARPI.
Emily MenendezCRPC | May 7, 2024
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
Zachary BessetteRLT | April 30, 2024
A CR was observed in the first patient with mCRPC to receive 2 cycles of 67Cu-SAR-bisPSMA at a dosage of 8GBq.
Advertisement
Advertisement
Advertisement